Medicare Proposes to Maintain Current Reimbursement Process for AlloMap
AlloMap is widely adopted by physician providers in over 90% of transplant centers across the US, has been the standard of care and incorporated into guidelines by the
The recently issued CMS memo was in response to a request made by a pathologist in
“AlloMap has stood the test the time and is now cemented as the standard of care, being part of ISHLT guidelines since 2010. We continue to generate new insights with AlloMap with a strong growing evidence base, and it is positive to see CMS evaluate this evidence and continue to support use of AlloMap,” said
“CareDx is appreciative of the thorough evidence reviews performed by CMS, which reaffirm the clinical utility of AlloMap, and supports the CMS proposal to continue the current reimbursement process through MACs. Our dedication to patients continues to provide relevant testing services that are well supported by clinical data,” said
Chief Marketing Officer
Source: CareDx, Inc.